Metformin Alkaloid-Int

Metformin, the active ingredient in Metformin Alkaloid-Int, is a biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control.

GNH USA supplies Metformin Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is a biguanide antidiabetic that acts on glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes: helps delay progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools that may be mild to moderate. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Hypoglycemia: primarily when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas reported in isolated cases.

Metformin requires careful monitoring in several clinical situations. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: evaluate liver enzymes to reduce risk of lactic acidosis. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia or metabolic acidosis. - Elderly patients: start at lower doses and titrate slowly. - Concomitant medications: review for drugs that may impair renal clearance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with other medicines, necessitating vigilance.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Alcohol (excessive): raises risk of lactic acidosis. - Carbamazepine: reduces metformin efficacy by increasing renal clearance. - Rifampicin: induces hepatic enzymes, lowering metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal function and metformin clearance. - ACE inhibitors: monitor renal function when combined. - NSAIDs: may impair renal perfusion, increasing metformin exposure. - Sulfonylureas: heightened risk of hypoglycemia when used together.